As Biotechnology companies, uniQure N.V. (NASDAQ:QURE) and Matinas BioPharma Holdings Inc. (NYSEAMERICAN:MTNB) are our subject to contrast. And more specifically their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure N.V.	11.28M	191.71	83.30M	-2.69	0.00
Matinas BioPharma Holdings Inc.	N/A	1265.25	14.99M	-0.16	0.00

Demonstrates uniQure N.V. and Matinas BioPharma Holdings Inc. earnings per share (EPS), top-line revenue and valuation.

Profitability

Table 2 provides the return on equity, return on assets and net margins of the two firms.

	Net Margins	Return on Equity	Return on Assets
uniQure N.V.	-738.48%	-58.5%	-35.9%
Matinas BioPharma Holdings Inc.	0.00%	0%	-104.5%

Risk and Volatility

uniQure N.V. has a 1.07 beta, while its volatility is 7.00%, thus making it more volatile than Standard and Poor’s 500. Matinas BioPharma Holdings Inc.’s 2.3 beta is the reason why it is 130.00% more volatile than Standard and Poor’s 500.

Liquidity

The Current Ratio and Quick Ratio of uniQure N.V. are 7.6 and 7.6 respectively. Its competitor Matinas BioPharma Holdings Inc.’s Current Ratio is 2.9 and its Quick Ratio is 2.9. uniQure N.V. can pay off short and long-term obligations better than Matinas BioPharma Holdings Inc.

Analyst Recommendations

The Recommendations and Ratings for uniQure N.V. and Matinas BioPharma Holdings Inc. are featured in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
uniQure N.V.	0	0	8	3.00
Matinas BioPharma Holdings Inc.	0	0	0	0.00

uniQure N.V.’s average target price is $78.5, while its potential upside is 35.16%.

Institutional and Insider Ownership

Institutional investors held 78.9% of uniQure N.V. shares and 11.7% of Matinas BioPharma Holdings Inc. shares. 2.2% are uniQure N.V.’s share held by insiders. Competitively, Matinas BioPharma Holdings Inc. has 0.7% of it’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
uniQure N.V.	6.3%	73.4%	107.66%	40.7%	137.94%	106.07%
Matinas BioPharma Holdings Inc.	18.35%	17.27%	54.07%	200%	27.72%	116.81%

For the past year uniQure N.V. has weaker performance than Matinas BioPharma Holdings Inc.

Summary

On 6 of the 10 factors Matinas BioPharma Holdings Inc. beats uniQure N.V.

uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The companyÂ’s principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics, and Chiesi Farmaceutici S.p.A. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing therapeutics for the treatment of fungal and bacterial infections. The company develops orally delivered therapeutics based on a proprietary, lipid-based drug delivery platform called cochleate delivery technology. Its lead product candidate is MAT 2203, an orally-administered cochleate formulation of the broad spectrum anti-fungal drug amphotericin B that is in Phase II study for the treatment of fungal infections. The company is also involved in developing MAT2501, an orally-administered, encochleated formulation of aminoglycoside antibiotic agent amikacin for acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram negative bacterial infections. In addition, it is exploring strategic partnership options for MAT8800 discovery program, which intends to identify product candidates derived from omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.